Agenix Limited  announced that Japan's Patent Office had granted a key patent covering the manufacturing process of its ThromboView® imaging agent for the detection of blood clots in humans. Agenix Chairman and Chief Executive Officer, Nicholas Weston said, "The granting of patent protection in Japa more

GE Healthcare announced that it has completed the acquisition of Xcellerex, Inc., a supplier of manufacturing technologies for the fast-growing biopharmaceutical industry. The acquisition expands GE Healthcare’s offering of technologies and services for the manufacture of biopharmaceuticals such as more

4-Antibody AG and Evotec AG announced the signing of a strategic collaboration agreement under which Evotec will offer a fully integrated antibody discovery and development service. Evotec’s novel and unique high throughput and high content screening approach coupled with 4-Antibody’s high throughpu more

Algeta ASA announced that its research collaboration with Sanofi (previously Genzyme) has been extended. This collaboration, which was announced in April 2011, is focused on evaluating the potential of linking the alpha-emitter thorium-227 to a proprietary antibody from Genzyme to create a tumor-tar more

UCB and Amgen announced the start of their sclerostin antibody (CDP7851/AMG 785) Phase 3 clinical trial program for the treatment of postmenopausal osteoporosis."We look forward to working with UCB on the CDP7851/AMG 785 Phase 3 program," said Sean E. Harper, M.D., executive vice president of Resear more

The efficiency of antibody molecules is dependent on their stability. We introduce an assay setup where stability of antibodies is measured. Shaking stress is initiated by the FLUOstar Omega microplate reader and aggregation propensity of antibody candidates is measured in 96-well format more

Biomarkers are currently changing the way we diagnose and treat diseases. Today pharmacodynamic biomarkers are widely used in the industry elaborating optimal dosing of new drugs and predictive biomarkers have an enormous potential for companion diagnostics more

As demonstrated here, there are a broad range of HPLC applications used in development, production, validation and release of protein therapeutics for human use. Some of the applications mentioned above are mandatory when submitting a new biopharmaceutical to approval at the regulatory agencies. The introduction of the first so-called biosimilars in Europe further increased the demand for highly efficient analysis methods. The continuous development of new stationary phases for the common modes of biochromatography, such as size exclusion, ion exchange and hydrophilic interaction chromatography support biochemists in increasing lab productivity and establishing high-throughput HPLC analysis not only for small molecules but also for large biopolymers more

Each antibody-antigen interaction has unique characteristics. A protocol giving good results for one antibody-antigen pair might found to be unsatisfactory for a second antibody even on the same sample. The interaction of antisera with protein epitopes in Western blot dependens upon a number of factors, all contributing to the final signal/noise ratio. Knowledge and control of those factors allows for modifications and optimization of the procedure. Polyclonal antibodies (serum or IgY-fractions from egg yolk) usually contain a number of different antibodies interacting independently with different epitopes on the target used for immunization. This number is limited for peptide-antigens but if recombinant or native proteins have been used for immunization the signal obtained has to be regarded as cumulative (=caused by several different types of antibodies present in the serum/IgY used) more

FuGENE® HD Transfection Reagent is well-suited for studying the impact of apoptosis-inducing proteins such as bax. Transfection with FuGENE® HD Transfection Reagent produced only minimal cytotoxic side effects while maintaining a high transfection efficiency. In contrast, cytotoxicity, and off-target effects of the other commercially available transfection reagents tested made it impossible to distinguish the impact of the bax protein from the impact of the transfection reagent itself more